Last reviewed · How we verify
15-Valent Pneumococcal Conjugate Vaccine
The 15-Valent Pneumococcal Conjugate Vaccine, marketed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, holds a significant position in the pneumococcal vaccine market. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity and revenue streams. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market valuation.
At a glance
| Generic name | 15-Valent Pneumococcal Conjugate Vaccine |
|---|---|
| Sponsor | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About How a New Pneumococcal Vaccine Works in Children (PHASE2)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: